TargetBeta
FAP
fibroblast activation protein alpha · also DPPIV · DASH family
10 programs in company-led studies act on FAP, from 9 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Lutetium-177 | Novartis | phase 3 | 2420 running | ERBB2 | the company's pipeline |
| Gallium-68 | Philogen | phase 3 | 179 running | ERBB2 | the company's pipeline |
| Fluorine F 18 FAPI-74rule | SOFIE | phase 3 | 32 running | – | NCIt |
| Fluorine F 18 FPyQCPrule | Bracco | phase 2 | 11 running | – | NCIt |
| HRS-6768 | Jiangsu HengRui Medicine | phase 2 | 11 running | – | the company's pipeline |
| Anti-FAP Antibody-drug Conjugate OMTX705rule | Oncomatryx Biopharma S.L. | phase 1 | 22 running | – | NCIt |
| Gallium Ga 68 NNS309 | Novartis | phase 1 | 22 running | – | the company's pipeline |
| Actinium Ac 225 RTX-2358rule | Ratio Therapeutics | phase 1 | 11 running | – | NCIt |
| Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050rule | Immunome | phase 1 | 11 running | – | NCIt |
| Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713rule | Eli Lilly | phase 1 | 11 running | – | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Breast Neoplasms, 2 programs
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Colorectal Neoplasms, 2 programs
- Prostatic Neoplasms, 2 programs
- Carcinoma, Renal Cell, 1 program
- Esophageal Neoplasms, 1 program
- Gastrointestinal Neoplasms, 1 program
- Glioblastoma, 1 program
- Neuroendocrine Tumors, 1 program
- Ovarian Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Lutetium-177 · Novartis · phase 3 · NCT05884255
- Jun 2027Gallium-68 · Philogen · phase 3 · NCT05706129
- Aug 30, 2027Fluorine F 18 FAPI-74 · SOFIE · phase 3 · NCT07217704
- Dec 2027Anti-FAP Antibody-drug Conjugate OMTX705 · Oncomatryx Biopharma S.L. · phase 1 · NCT05547321
- Jan 2028Actinium Ac 225 RTX-2358 · Ratio Therapeutics · phase 1 · NCT07156565
- Jan 16, 2028Gallium Ga 68 NNS309 · Novartis · phase 1 · NCT07630961
- Jan 31, 2028Fluorine F 18 FPyQCP · Bracco · phase 2 · NCT07432633
- Jul 2028Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713 · Eli Lilly · phase 1 · NCT07213791
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.